Anaemia in heart failure: A prospective evaluation of clinical outcome in a community population

Heart Lung and Circulation

Volumn 19, Issue 12, 2010, Pages 730-735

  Stewart, Tanya ^a   Freeman, Jane ^b   Stewart, Jessica ^b   Sullivan, Anne ^a   Ward, Christopher ^b   Tofler, Geoffrey H ^b  

^a Department of Palliative Care   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Anaemia; Community cardiology population; Heart failure

Indexed keywords

ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SPIRONOLACTONE;

ADULT; AGED; ANEMIA; ANTICOAGULATION; ARTICLE; COMMUNITY; CREATININE BLOOD LEVEL; CYANOCOBALAMIN DEFICIENCY; DISEASE ASSOCIATION; DRUG USE; FEMALE; FOLIC ACID DEFICIENCY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL READMISSION; HUMAN; HYPONATREMIA; IRON DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; AUSTRALIA; FEMALE; HEART FAILURE; HOSPITALS, COMMUNITY; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PATIENT READMISSION; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 78149468082     PISSN: 14439506     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hlc.2010.08.004     Document Type: Article

References (21)

1. Volpe M., Tritto C., Testa U. Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am J Cardiol 1994, 74:468-473.
2. Sharma R., Francis D.P., Pitt B., Poole-Wilson P.A., Coats A.J., Anker S.D. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J 2004, 25:1021-1028.
3. Anand I., McMurray J.J., Whitmore J., Warren M., Pham A., McCamish M.A., Burton P.B. Anaemia and its relationship to clinical outcome in heart failure. Circulation 2004, 110:149-154.
4. Al-Ahmad A., Rand W.M., Manjunath G., Konstam M.A., Salem D.N., Levey A.S., Sarnak M.J. Reduced kidney function and anaemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001, 38:955-962.
5. Felker G.M., Gattis W.A., Leimberger J.D., Adams K.F., Cuffe M.S., Gheorghiade M., O'Connor C.M. Usefulness of anaemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol 2003, 92:625.
6. National Kidney Foundation Am J Kidney Dis 2001, 37:S182-S238.
7. da Silva L.B., Rohde L.E., Clausell N. Etiology and management of anaemia in patients with heart failure: How much Iron is missing?. Congest Heart Fail 2008, 14:25-30.
8. Tang Y., Katz S. Anaemia in Chronic Heart Failure - Prevalence, Etiology, Clinical Correlates, and Treatment Options'. Circulation 2006, 113:2454-2461.
9. Cromie N, Lee C., Struthers A.D. Anaemia in Chronic Heart Failure: what is its frequency in the UK and its underlying causes?. Heart 2002, 87:377-378.
10. Nanas J.N., Matsouka C., Karageorgopoulos D. Etiology of anaemia in patients with advanced heart failure. J Am Coll Cardiol 2006, 48:2485-2489.
11. Silverberg D.S., Wexlex D., Blum M., Keren G., Sheps D., Leibovitch E., et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of severe, resistant congestive cardiac failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000, 35:1737-1744.
12. Weiss G., Goodnough L.T. Anaemia of chronic disease. N Engl J Med 2005, 352:1011-1023.
13. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anaemia of inflammation. Blood 2003, 102:783-788.
14. Rodriguez J.A., Chamorro G.A., Rapaport E. Effect of isovolemic anemia on ventricular performance at rest and during exercise. J Appl Physiol 1974, 36:28-33.
15. Vasan R.S., Larson M.G., Benjamin E.J. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction - prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999, 33:1948-1955.
16. Groenveld H.F., Januzzi J.L., Damman K., Van Wijngaarden J., Hillege H.L., Van Veldhuisen D.J., et al. Anaemia and mortality in heart failure patients: a systematic review and meta-analysis. J Am Coll Cardiol 2008, 52:818-827.
17. Palazzuoli A., Silverberg D., Iovine F., et al. Erythropoietin improves anaemia, exercise tolerance and renal function, and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anaemia. Am Heart J 2006, 152:e9-e15.
18. Van der Meer P., Lipsic E., Henning R.H., et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005, 46:125-133.
19. Sandhu A., Soman S., Hudson M., Besarab A. Managing anemia in patients with chronic heart failure: what do we know?. Vasc Health Risk Manage 2010, 6:237-252.
20. Hebert P.C., Wells G., Blajchman M.A. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999, 340:409-417.
21. Choy C.K., Spencer A.P., Nappi J.M. Prevalence of anaemia in clinic patients with heart failure and cost analysis of epoetin treatment. Pharmacotherapy 2007, 27:707-714.